Dactinomycin

Các tên gọi khác (10 ) :

2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
ActD
Actinomycin C1
Actinomycin D
Actinomycin iv
Dactinomicina
Dactinomycin
Dactinomycine
Dactinomycinum
Meractinomycin

Thuốc chống ung thư và tác động vào hệ thống miễn dịch

Thuốc Gốc

Small Molecule

CAS: 50-76-0

ATC: L01DA01

ĐG : Lundbeck Inc. , http://www.lundbeckinc.com

CTHH: C₆₂H₈₆N₁₂O₁₆

PTK: 1255.417

A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

Nhận Dạng Quốc Tế & Đặc Tính Hóa Học

Công thức hóa học

C₆₂H₈₆N₁₂O₁₆

Phân tử khối

1255.417

Monoisotopic mass

1254.628474764

InChI

InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

InChI Key

InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N

IUPAC Name

1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

Traditional IUPAC Name

actinomycin D

SMILES

[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C

Độ tan chảy

241.5-243 °C

Độ hòa tan

Soluble at 10 °C

logP

1.6

logS

-4.8

pKa (strongest acidic)

10.52

pKa (Strongest Basic)

-0.13

PSA

355.54 Å²

Refractivity

326.17 m³·mol^-1

Polarizability

129.2 Å³

Rotatable Bond Count

H Bond Acceptor Count

H Bond Donor Count

Physiological Charge

Number of Rings

Bioavailability

MDDR-Like Rule

true

Dược Lực Học : Generally, the actinomycins exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. Because the actinomycins are cytotoxic, they have an antineoplastic effect which has been demonstrated in experimental animals with various types of tumor implant. This cytotoxic action is the basis for their use in the treatment of certain types of cancer. Dactinomycin is believed to produce its cytotoxic effects by binding DNA and inhibiting RNA synthesis.

Cơ Chế Tác Dụng : A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA (prevention of RNA polymerase elongation) and, consequently, with protein synthesis.

Dược Động Học :

▧ Absorption :
poorly absorbed from gastrointestinal tract
▧ Protein binding :
5%
▧ Metabolism :
hepatic
▧ Half Life :
36 hours

Độc Tính : hepatoxicity

Chỉ Định : For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen

Tương Tác Thuốc :

Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

Liều Lượng & Cách Dùng : Powder, for solution - Intravenous

Dữ Kiện Thương Mại

Giá thị trường

Biệt dược thương mại : Cosmegen 0.5 mg vial

Giá bán buôn : USD >684.36

Đơn vị tính : vial

Nhà Sản Xuất

Công ty : Lundbeck

Sản phẩm biệt dược : Cosmegen
Công ty : Lundbeck

Sản phẩm biệt dược : Lyovac Cosmegen

Đóng gói

Công ty : Lundbeck Inc.

Website : http://www.lundbeckinc.com
Công ty : Merck & Co.

Website : http://www.merck.com

Tài Liệu Tham Khảo Thêm

drugbank

http://www.drugbank.ca/drugs/DB00970

KEGG Compound

http://www.genome.jp/dbget-bin/www_bget?cpd:C06770

KEGG Drug

http://www.genome.jp/dbget-bin/www_bget?drug:D00214

BindingDB

http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50023797

PharmGKB

http://www.pharmgkb.org/drug/PA151917012

Wikipedia

http://en.wikipedia.org/wiki/Dactinomycin

RxList

http://www.rxlist.com/cgi/generic2/dactinomycin.htm

Drugs.com

http://www.drugs.com/cdi/dactinomycin.html

Bạn thấy hài lòng ?

Bạn chưa hài lòng ?

... loading